Loading clinical trials...
Loading clinical trials...
A Single-Arm, Open-Label, Phase II Study to Assess the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Conditions
Interventions
catumaxomab
Locations
18
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
University of San Diego
La Jolla, California, United States
Stanford University Hospital and Clinics
Stanford, California, United States
University of Miami
Miami, Florida, United States
Florida Hospital Cancer Center
Orlando, Florida, United States
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
Start Date
June 1, 2006
Primary Completion Date
December 1, 2009
Completion Date
August 1, 2010
Last Updated
October 17, 2018
NCT06016179
NCT02122185
NCT05303844
NCT02477657
NCT03200106
NCT03230708
Lead Sponsor
Neovii Biotech
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions